Clinical Trials

A first-in-human trial is assessing the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of STX-721 as a monotherapy for patients with non–small cell lung cancer with EGFR exon 20 insertion mutations.

The ADVANCED-2 trial plans to build onto the early antitumor and safety data seen with TARA-002 that were presented this year for patients with non-muscle invasive bladder cancer.

ABM-1310 is an investigational small molecule BRAF inhibitor that is being development for the treatment of various BRAF V600E-mutant solid tumors.

The investigational antibody-drug conjugate, MYTX-011, is one step further in development for the treatment of non–small cel lung cancer with cMET overexpression.

Following positive phase 1 results, HPN328 treatment in now under evaluation in a phase 1/2 trial.

A new treatment geared to treat the most common driver of RAS-addicted solid tumors has been dosed for the first time in humans.

Two doses of CD40HVac, a therapeutic vaccine targeting dendritic cells, are being evaluated as treatment for HPV-positive oropharyngeal cancer in a phase 1/2a trial.

The investigational PLK1 inhibitor, CYC140, is the focus of important clinical research in advanced solid tumors, leukemias, and lymphomas.

A phase 1 trial will evaluate OSM-0205 in healthy subjects with chemotherapy-induced peripheral neuropathy, followed by a phase 2 study in patients with breast cancer.

According to Ruben A. Mesa, MD, FACP, confirming the benefit of long-acting interferon for essential thrombocytopenia is key.

As determined by phase 1 of the ARROS-1 study, patients with ROS1-positive non–small cell lung cancer and other solid tumors will be further assessed with the recommended phase 2 dose of NVL-520 in phase 2 of the trial.

Treatment with an investigational mitochondrial inhibitor and bevacizumab has started in a phase 1b clinical trial of patients with previously-treated metastatic colorectal cancer.

Ivonescimab is being investigated in phase 3 clinical trial against the combination of tislelizumab and chemotherapy.

Fadraciclib, a highly selective inhibitor of CDK2 and CDK9, is being investigated in clinical trials for patients with solid tumors and hematologic malignancies.

A number of trials evaluating rintatolimod as a combinational therapy for a wide range of solid tumor types are underway and planned, including in pancreatic and breast cancer.

After success, preclinically and in a phase 1 dose-finding study, the phase 2 study of BDC-1001 has begun.

For the first time ever, patients with relapsed or refractory B-cell non-Hodgkin lymphoma can receive the experimental chimeric antigen receptor T-cell therapy, CLN-978, in a clinical trial.

Determining the safety and efficacy of zipalertinib combined with chemotherapy for patients with EGFR exon 20 insertion mutation-positive non–small cell lung cancer are the key goals of the newly-launched phase 3 REZILIENT3 study.

The phase 1 study is evaluating the combination of a CD19-targeting chimeric antigen receptor and an orthogonal IL-2 in patients with CD19-positive hematologic malignancies.

Treatment has been initiated in a phase 1/2 study of TNG260 added to pembrolizumab in patients with advanced or metastatic solid tumors.

Investigators are evaluating the efficacy and safety of selinexor vs placebo when used as a maintenance therapy for patients with p53 wild-type advanced or recurrent endometrial cancer.

A total of 110 patients with Bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer have been enrolled in a phase 3 study evaluating cretostimogene grenadenorepvec.

In an interview with Targeted Oncology, Lucia Masarova, MD, discussed the ongoing EXCEED-ET clinical trial and its potential to provide a new option to alter disease and ward off post-essential thrombocytopenia myelofibrosis in adult patients.

Following early efficacy demonstrated with DKN-01, bevacizumab, and chemotherapy in part A of the DeFianCe study, part B has begun enrolling patients with advanced colorectal cancer.

An investigation of selective targeting of A2AR in patients with certain solid tumors is underway in a first-in-human study.

In season 4, episode 9 of Targeted Talks, Kerry Reynolds, MD, discusses the occurrence of myocarditis in patients with cancer treated with immune checkpoint inhibitors.

Treatment with the investigational drug FHD-286 exhibits positive results in patients with metastatic uveal melanoma and will be explored further in acute myeloid leukemia and myelodysplastic syndrome.

A phase 1 study is assessing the safety and tolerability of briquilimab in patients with lower-risk myelodysplastic syndrome.

E-602 represents the first glyco-immune checkpoint inhibitor and the early safety as well as translational immunology associated with the treatment in patients with advanced cancer is promising, according to Jason Luke, MD, FACP.

According to the developer of TTI-101, the REVERT-Liver Cancer trial is the second of three phase 2 trials involving the agent.